Navigation Links
HRID Expands Distribution of Azul Instant™ Into Puerto Rico
Date:2/27/2012

FORT LAUDERDALE, Fla., Feb. 27, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals (soon to be changed from Hybrid Fuels, Inc.) (Pink Sheets: HRID) announced today that it will expand distribution of Azul Instant™ into the Puerto Rico market.     

"We have selected Puerto Rico as our next target market outside of the U.S. based on our existing relationships with drug wholesalers/ distributors across the island and the significant growth of natural cures and supplements over the past couple of years.  The culture embraces all-natural products and we believe this will represent significant sales, revenue and profit potential for Nouveau Life Pharmaceuticals," stated Ramiro Cadena, CEO of Nouveau Life Pharmaceuticals.    

The Company recently announced the introduction of Azul Instant™, an all-natural supplement for erectile dysfunction (ED) that provides the millions of men suffering from the condition with a safe alternative to prescription drugs.  Developed by a team of experts, the Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated. Unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects. 

About Azul Instant™

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals.  The Company developed the formula to provide a safe and natural alternative for erectile dysfunction.  Patients will now receive the NATURAL benefits of Azul Instant™ without experiencing the side effects associated with prescription medications.  While there are other natural alternative supplements on the market today, Azul Instant™ is the only male enhancement product that works within 5 minutes.  Azul Instant™ lasts for up to 48 hours and has proven to help enhance sexual stamina, endurance, strength and energy with no side effects. 

Azul Instant™ is marketed under Nouveau Life Pharmaceuticals, Inc.  For more information, go to www.azulnow.com

About Hybrid Fuels, Inc.

The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.; Hybrid Fuels, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... Au Pair comes all the way around the world to provide child care ... often worried things won’t go well. More often than not, however, they find out their ... Year winner’s all commented how their Au Pairs have become a part of the family, ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):